Experimental cell therapy for advanced HER2-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic HER2-negative breast cancer that cannot be removed by surgery.
- You cannot have had the same chemotherapy or immunotherapy drugs used in this trial before for your advanced cancer, or if you had them earlier, it must be at least 12 months ago.
- You must have lymph nodes near the tumor that a doctor can surgically remove to grow special immune cells.
- You need to be generally healthy enough for surgery and the study drugs, with good organ function (like kidneys, liver, heart, and lungs).
- If you have hormone receptor-positive breast cancer, you must have already tried at least one hormone therapy or CDK4/6 inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using your own immune cells taken from lymph nodes near the tumor. The cells are grown in a lab and given back to you to fight cancer, along with another drug chosen by your doctor.
This trial tests whether using a patient's own immune cells from lymph nodes near the tumor, given as a treatment before surgery, can help shrink HER2-negative breast cancer. It is for people whose cancer has not responded fully to two cycles of initial chemotherapy.
This trial tests whether taking immune cells from your lymph nodes and giving them back to you can help shrink breast cancer that has not responded fully to initial chemotherapy. It is for women with HER2-negative breast cancer who have had stable disease after two cycles of a standard chemotherapy combination.
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.